OTS - IgNova files patent application on antibody against COVID-19
2020. June 23. 17:27
Visbek, June 23, 2020 (APA/OTS) - IgNova announced today that it
has filed a patent application covering the use of passive
immunization to control SARS-CoV-2 infection in humans. IgNova, a
biopharmaceutical R&D start up, researches technology based on
specific egg immunoglobulins (IgY).
The patented IgY binds the spike protein of SARS-CoV-2,
neutralizing the virus when it enters the mouth or nose and,
therefore, inhibiting the infection process. IgNova's technology
offers a safe, economical, and unlimited source of polyclonal
antibodies to control SARS-CoV-2.
The IgY antibody technology has a wide range of applications
such as chewable tablets, sprays, or mouthwash, offering instant
protection against SARS-CoV-2. Additional applications, such as
IgY-coated air filters and masks, could potentially support medical
professionals and other at-risk professions. With antigen and
antibody production as well as specific applications included in
the patent, IgNova envisions an exhaustive IgY technology response
to COVID-19.
"We are at the final research stage," says Michael Gerrits,
IgNova Managing Director, "working closely with scientific
institutions and potential strategic partners to bring the
technology to market. We have started initial testing with the
objective to allow our partners to introduce IgNova technology
based products to market in Q4 2020."
IgNova's patent is based on proprietary IgY technology, a
process that involves immunizing chickens against target pathogens,
extracting antibodies from eggs. IgY technology was developed in
the 1980s to help control dental caries. In Japan, the technology
is widely used both in food and human health applications.
"Early research looks promising," says IgNova Managing Director
Tonchy Ugrinovic. "With the right scientific and production
partners, IgNova targets a mass-marketable solution in Q4 of this
year 2020."
About IgNova
Founded in 2013, IgNova is a biopharmaceutical R&D start up
that drives IgY technology innovation in accordance with stringent
quality management and design control standards. At production
sites in the US, Japan, and Europe, cutting-edge health and safety
solutions are developed in close collaboration with industry
partners.
Contact
Pia Becker
Tel: +49 4445 9868174
Mobile: +49 151 10464268
Email: contact@ignova.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.